In this study, the authors shed new light on the pathophysiology underlying the cardiomyopathy of Barth syndrome (BTHS), a mitochondrial disorder caused by a mutation on the tafazzin (TAZ) gene, by combining tissue engineering with patient‐derived and genetically engineered iPSCs.72 Furthermore, the authors were able to assess the effect of potential therapies for Barth syndrome using these BTHS iPSC‐derived cardiomyocytes. The gene discussed is TAFAZZIN; the disease is cardiomyopathy.